Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback